ID
IDGXF.US Integrated Diagnostics Holdings plc
- Market cap
- USD 349M
- P/E
- 12.0x
- P/B
- 4.77x
- ROE
- 41.9%
- Dividend yield
- 1.41%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is IDGXF.US undervalued?
Graham numberIDGXF.US trades 59.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Integrated Diagnostics Holdings plc fundamental analysis
No fundamental analysis for Integrated Diagnostics Holdings plc yet.
Integrated Diagnostics Holdings plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Integrated Diagnostics Holdings plc
Integrated Diagnostics Holdings plc, a consumer healthcare company, provides medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, such as positron emission tomography - computed tomography (PET-CT), MRI, computed tomography (CT), mammography…
Full company profileIntegrated Diagnostics Holdings plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Integrated Diagnostics Holdings plc annual financial statements (EGP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.17B | 1.51B | 1.92B | 2.23B | 2.66B | 5.22B | 3.61B | 4.12B | 5.72B | 7.86B | 9.71B |
| Gross Profit | 628M | 730M | 948M | 1.08B | 1.34B | 2.80B | 1.46B | 1.52B | 2.18B | 3.35B | 4.21B |
| Operating Income | 466M | 540M | 685M | 791M | 986M | 2.26B | 832M | 738M | 1.21B | 2.12B | 2.65B |
| EBITDA | 443M | 631M | 807M | 973M | 1.22B | 2.57B | 1.17B | 1.28B | 2.09B | 2.89B | 3.02B |
| Net Income | 260M | 374M | 502M | 511M | 594M | 1.41B | 541M | 510M | 1.08B | 1.26B | 1.64B |
| EPS | 0.43 | 0.62 | 0.84 | 0.85 | 0.99 | 2.35 | 0.90 | 0.85 | 1.82 | 2.17 | 2.83 |
| Balance Sheet | |||||||||||
| Total Assets | 3.05B | 3.11B | 3.43B | 3.76B | 4.18B | 6.24B | 5.30B | 5.77B | 7.13B | 8.60B | 9.31B |
| Total Liabilities | 746M | 798M | 1.03B | 1.40B | 1.75B | 3.44B | 2.85B | 2.67B | 3.63B | 4.46B | 4.59B |
| Shareholders' Equity | 2.24B | 2.25B | 2.27B | 2.22B | 2.27B | 2.58B | 2.15B | 2.68B | 2.71B | 3.38B | 3.93B |
| Cash & Short-term Investments | 779M | 694M | 653M | 631M | 877M | 2.35B | 816M | 861M | 1.75B | 2.13B | 1.96B |
| Total Debt | 152M | 171M | 217M | 445M | 552M | 859M | 1.18B | 1.18B | 1.47B | 1.61B | 1.68B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 399M | 403M | 556M | 697M | 883M | 2.27B | 209M | 544M | 1.57B | 1.90B | - |
| Capital Expenditure | 48.5M | 157M | 332M | 218M | 126M | 264M | 309M | 326M | 225M | 521M | 0.00 |
| Free Cash Flow | 350M | 246M | 225M | 479M | 757M | 2.01B | -100M | 218M | 1.34B | 1.38B | - |
| Ratios | |||||||||||
| ROE | 11.6% | 16.7% | 22.1% | 23.1% | 26.2% | 54.7% | 25.1% | 19.0% | 39.8% | 37.3% | 41.9% |
| ROA | 8.5% | 12.0% | 14.6% | 13.6% | 14.2% | 22.7% | 10.2% | 8.8% | 15.1% | 14.7% | 17.7% |
| Net Profit Margin | 22.2% | 24.7% | 26.1% | 22.9% | 22.4% | 27.0% | 15.0% | 12.4% | 18.8% | 16.1% | 16.9% |
| Debt to Equity | 0.07x | 0.08x | 0.10x | 0.20x | 0.24x | 0.33x | 0.55x | 0.44x | 0.54x | 0.48x | 0.43x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Integrated Diagnostics Holdings plc dividends
- Dividend yield
- 1.41%
- Forward dividend
- 0.01 USD
- Payout ratio
- 42.4%
- Ex-dividend date
- May 28, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EGP 535M | 0.92 | 42.4% |
| 2024 | EGP 27.4M | 0.05 | 2.5% |
| 2023 | - | - | - |
| 2022 | EGP 1.41B | 2.35 | 260.9% |
| 2021 | USD 479M | 0.80 | 33.9% |
| 2020 | USD 451M | 0.75 | 75.9% |
| 2019 | USD 451M | 0.75 | 88.2% |
| 2018 | USD 435M | 0.72 | 86.6% |
| 2017 | EGP 377M | 0.63 | 100.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 4:1 on Dec 24, 2020.
Who owns Integrated Diagnostics Holdings plc
- Insiders 61.41%
- Institutions 38.59%
- Public & others 0.00%
- Shares outstanding 581M
- Free float 125M
Integrated Diagnostics Holdings plc company profile
- Company name
- Integrated Diagnostics Holdings plc
- Ticker
- IDGXF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7,137
- Fiscal year end
- December
- Address
- 12 Castle Street, Saint Helier, Jersey, JE2 3RT
- Phone
- 44 15 3484 7000
- Website
- idhcorp.com
About Integrated Diagnostics Holdings plc
Integrated Diagnostics Holdings plc, a consumer healthcare company, provides medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, such as positron emission tomography - computed tomography (PET-CT), MRI, computed tomography (CT), mammography, ultrasound, X-Ray, electromyography, electroencephalography, electroencephalogram, and electrocardiogram, as well as operates cath lab facilities. It operates in Egypt, Sudan, Nigeria, and the Kingdom of Saudi Arabia. The company was founded in 1979 and is based in Saint Helier, Jersey.
Integrated Diagnostics Holdings plc management
3- Prof. Hend El Sherbini Ph.D.Group CEO & Executive Director · born 1969
- Mr. Sherif Mohamed Mohamed El ZeinyVP, Group CFO & Executive Director
- Mr. Tarek YehiaDirector of Investor Relations